Alterity Therapeutics Ltd. logo

Alterity Therapeutics Ltd. (ATHE)

Market Open
11 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
4. 59
+0.7
+17.99%
$
67.95M Market Cap
- P/E Ratio
0% Div Yield
658,400 Volume
0 Eps
$ 3.89
Previous Close
Day Range
4.5 5.51
Year Range
1 5.87
Want to track ATHE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 20 days

Summary

ATHE trading today higher at $4.59, an increase of 17.99% from yesterday's close, completing a monthly increase of 10.07% or $0.42. Over the past 12 months, ATHE stock gained 37.01%.
ATHE is not paying dividends to its shareholders.
The last earnings report, released on Aug 29, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Aug 04, 2025.
Alterity Therapeutics Ltd. has completed 2 stock splits, with the recent split occurring on Jan 09, 2023.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

ATHE Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Alterity (ATHE) Up on Interim Data From Advance MSA Study

Alterity (ATHE) Up on Interim Data From Advance MSA Study

Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises.

Zacks | 0 year ago

Alterity Therapeutics Ltd. Dividends

ATHE is not paying dividends to its shareholders.

Alterity Therapeutics Ltd. Earnings

4 Aug 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
29 Aug 2024 Date
-
Cons. EPS
-
EPS
28 Aug 2024 Date
-
Cons. EPS
-
EPS
20 Aug 2024 Date
-
Cons. EPS
-
EPS
30 Apr 2024 Date
-
Cons. EPS
-
EPS
ATHE is not paying dividends to its shareholders.
4 Aug 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
29 Aug 2024 Date
-
Cons. EPS
-
EPS
28 Aug 2024 Date
-
Cons. EPS
-
EPS
20 Aug 2024 Date
-
Cons. EPS
-
EPS
30 Apr 2024 Date
-
Cons. EPS
-
EPS

Alterity Therapeutics Ltd. (ATHE) FAQ

What is the stock price today?

The current price is $4.59.

On which exchange is it traded?

Alterity Therapeutics Ltd. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is ATHE.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 67.95M.

When is the next earnings date?

The next earnings report will release on Aug 04, 2025.

Has Alterity Therapeutics Ltd. ever had a stock split?

Alterity Therapeutics Ltd. had 2 splits and the recent split was on Jan 09, 2023.

Alterity Therapeutics Ltd. Profile

Biotechnology Industry
Healthcare Sector
David A. Stamler CEO
NASDAQ (CM) Exchange
02155X106 Cusip
AU Country
10 Employees
- Last Dividend
9 Jan 2023 Last Split
5 Sep 2002 IPO Date

Overview

Alterity Therapeutics Limited is a pioneering company focused on the development of novel therapeutics for the treatment of neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, Parkinson's disease, and other neurological disorders. The company, which has been operational since 1997, is located in Melbourne, Australia. Initially known as Prana Biotechnology Limited, it underwent a rebranding to Alterity Therapeutics Limited in April 2019. With its commitment to innovation in the field of neurological disorders, Alterity Therapeutics is at the forefront of research and development efforts to provide new treatment options for these challenging conditions.

Products and Services

  • ATH434

    ATH434 is Alterity Therapeutics' leading drug candidate currently in Phase I clinical trial, targeting the treatment of Parkinson's disease. This innovative therapeutic approach aims to offer a novel solution for managing and potentially altering the course of Parkinson's disease, shedding hope for those affected by this debilitating condition.

  • ATH434-201

    This derivative of ATH434 is in Phase II clinical trial, specifically designed to treat multiple system atrophy at an early stage. ATH434-201 represents a strategic expansion of the company's portfolio into addressing more specific neurodegenerative disorders within the spectrum of Parkinsonian syndromes.

  • ATH434-202

    Similar to ATH434-201 but focused on the advance stage of multiple system atrophy, ATH434-202 is also in Phase II clinical trial. This development underscores Alterity Therapeutics' dedication to providing treatments across different stages of neurodegenerative diseases, catering to a broader patient population.

  • PBT2

    Having completed a Phase 2a clinical trial, PBT2 addresses Alzheimer's disease, offering a potential treatment option for this profoundly impactful neurodegenerative condition. The completion of this trial stage marks a significant milestone in the quest for Alzheimer's disease therapies, indicating the company's ongoing commitment to groundbreaking research in neurological health.

Contact Information

Address: 460 Bourke Street
Phone: 61 3 9349 4906